IPP Bureau
Indian government approves eight firms for PLI scheme
By IPP Bureau - December 10, 2021
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Govt includes seven more companies under PLI scheme
By IPP Bureau - December 10, 2021
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
.jpg "Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials")
Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials
By IPP Bureau - December 10, 2021
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Dr Reddy’s launch Venlafaxine ER tablets in the US
By IPP Bureau - December 10, 2021
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
China approves Brii Bio’s antibody combination to neutralise Covid-19
By IPP Bureau - December 10, 2021
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Zydus receives USFDA approval for Phase2(b)/3 trial of Saroglitazar
By IPP Bureau - December 10, 2021
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Aerogen partners with CanSinoBIO for aerosolised Covid-19 vaccine
By IPP Bureau - December 10, 2021
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Algorithmic Biologics receives CE mark for Tapestry platform
By IPP Bureau - December 10, 2021
The platform’s technology works as a compression algorithm for molecular testing
Lupin enters the diagnostics business
By IPP Bureau - December 10, 2021
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Gland Pharma receives tentative approval for Cangrelor
By IPP Bureau - December 09, 2021
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
Alembic receives tentative USFDA approval for Selexipag tablets
By IPP Bureau - December 09, 2021
The tablets are indicated for the treatment of pulmonary arterial hypertension
USFDA authorises Astra’s antibody cocktail to prevent Covid
By IPP Bureau - December 09, 2021
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
Three doses of Pfizer-BioNTech vaccine protects against Omicron: Study
By IPP Bureau - December 09, 2021
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Doctors at Zydus hospital perform robotic-assisted surgery
By IPP Bureau - December 09, 2021
Whipple procedure is a very complex operation, mainly performed to remove pancreatic cancer
Dr Reddy’s and Prestige BioPharma collaborate to commercialise trastuzumab biosimilar
By IPP Bureau - December 09, 2021
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
